GT Biopharma (GTBP) Enterprise Value (2010 - 2026)

GT Biopharma (GTBP) has reported Enterprise Value for 17 consecutive years, with -$8.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Enterprise Value fell 276.93% year-over-year to -$8.4 million in Q1 2026; TTM through Mar 2026 was -$8.4 million, a 276.93% decrease from a year earlier, with the FY2025 full-year figure at -$3.8 million, down 1.31% from the prior year.
• Enterprise Value was -$8.4 million for Q1 2026 at GT Biopharma, down from -$3.8 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$2.2 million in Q1 2025 and troughed at -$32.7 million in Q2 2023.
• A 5-year average of -$13.4 million and a median of -$13.6 million in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value soared 87.17% in 2025 and slumped 276.93% in 2026, its largest moves.
• Over 5 years, Enterprise Value stood at -$15.3 million in 2022, then rose by 11.68% to -$13.6 million in 2023, then soared by 72.18% to -$3.8 million in 2024, then slipped by 1.31% to -$3.8 million in 2025, then sank by 120.96% to -$8.4 million in 2026.
• The last three Enterprise Value figures came in at -$8.4 million (Q1 2026), -$3.8 million (Q4 2025), and -$2.5 million (Q3 2025), per Business Quant data.